Home
overview

Integrating biobank systems with improved communication networks and global standardisation is essential as it has been projected that there will be approximately 200 biobanks operating across Europe alone in 2013. As researchers endeavour to develop more personalised medicines, acquiring high quality biospecimens is essential. This is reflected in the estimation that the global Biobanking market is expected to reach $183 billion in the next 5 years as biobanks experience rapid growth. SMi’s 3rd Annual Biobanking conference will aim to bring together key solution providers and potential clients affiliated with pharmaceutical companies and Biobanking institutions alike therefore providing an excellent platform for communication within the biobanking community.

SMi’s 3rd annual Biobanking event will reflect the significant change driving current development in biosample management and there will be efforts to link value to existing biological resources and coverage of important issues experienced by those who donate, manage and expend biobank samples. Focussing on the properties of data sharing and greater involvement between biobanks, allow Biobanking 2013 to give you the most up to date and relevant information on Biobanking today.

 

Comments from last years delegates included:

‘‘Entertaining and informative’’ – Roche
‘‘Stimulated, good discussions and provided good feedback on questions’’ – Merck
‘‘Interesting insight into an ethical/legal problem’’ – NIBSC
‘‘Detailed and specific’’ – GSK
‘‘Excellent insight!’’ – IRIS

 

  • Build strategic relationships between academia and industry
  • Unique insights into building and developing a successful biobanking infrastructure
  • Discuss key ethical and regulatory considerations with input from the Human Research Authority
  • Spotlight on ground-breaking topics that expose commercial opportunities for future investments
  • Explore Strategic Tissue Repository Alliances Through Unified Methods (STRATUM)
  • Promote availability and maximise value from biospecimen collections
  • Investigate ways in which biobanks can contribute to stratified medicine 

Heads of Department, Directors, Managers, Team Leaders of:

Biobanking
Biorepository
Biological Sample Management
Biosample Management
Pharmacogenomics
Pathology
Genomics
Personalised Medicine
Translational Medicine
Lab Management
Inventory Management
Molecular Technologies
Biologics Research
Data Privacy/Protection/Security Officers
Quality Control and Quality ManagementResearch and Development
Supply Chain
Population based biobanks
Disease based biobanks
Hospital Trusts
Research Institutes
Tecnology Transfer
Bioinnovation

 

 

AstraZeneca; Belgian Volition; Biokit S.A; BioM Biotech Cluster Development GmbH; BioStorage Technologies GmbH ; CellPath Ltd; Chernobyl Tissue Bank; Confederation of Cancer Biobanks; Covington & Burling Llp; Cytori Therapeutics , Inc.; Elpro UK Ltd; Genetic Alliance; GlaxoSmithKline; Helmholtz Zentrum M³nchen; Imperial College Of Science And Medicine; Independent Consultancy ; Institute Of Neurology; IRIS; Janssen-Cilag E M E A; Karolinska Institute; Karolinska Institutet; Kings College London; Labvantage Solutions; Labvantage Solutions Inc; Leo Pharma; McGill University Department of Human Genetics; Merck Research Laboratories; Ministry Of Public Health; Moorfields Eye Hospital; National Cancer Institute; National Institute For Biological Standards & Control; NCRI; Newcastle Biomedicine Clinical Research Platforms; Newcastle University; Newcastle upon Tyne Hospitals NHS Trust; NIBSC; NIH\NCI\OBBR; NIHR Biomedical Research Centre; Norwegian University Of Science And Technology; Nottingham University Hospital NHS Trust; Novartis Horsham Research Centre; Novartis International AG; Pasteur Hopital, University of Nice; QuickSTAT; ROCHE; Roche Products; Roche Products Ltd; Roswell Park Cancer Institute State University of New York at Buffalo; Royal Free Hospital; Sera Laboratories International Ltd; Southend University Hospital; St Marys Hospital; Sysmex UK Ltd; Technology Networks; The Automation Partnership Limited; Tissue Solutions; UCL Medical School; UCL Medical School Royal Free Campus; University College London; University of Heidelberg; University of Leicester; University Of Liverpool; university of manchester school of translational medicine; University of Westminster; Vindon Scientific Ltd; Welcome Trust;
 

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Pedro  Rondot Radio

Pedro Rondot Radio, Executive Director, University of Buenos Aires

9:10 Consent for biobanking - a partnership approach

Balwir Matharoo Ball

Balwir Matharoo Ball, Operations Manager Trasitional Research & Biobanking, Nottingham University Hospitals NHS Trust

  • Commitment to broad and enduring consent
  • Permission to gather detailed clinical phenotype
  • Patient led consent
  • Maintaining confidence and confidentiality
  • Controlling access to information
  • 9:50 Ensuring sample integrity and aiding loss prevention through effective monitoring

    Peter Jackson

    Peter Jackson, Managing Director, Elpro UK Ltd

  • Functionality – what should a monitoring system do
  • Implementation and operation – points to consider for Biobanks
  • Using the measurement results to improve processes and avoid losses
  • 10:30 Morning Coffee

    10:50 Global biobank governance and sample collection strategies within AstraZeneca

    Douglas McKechnie

    Douglas McKechnie, Biobank Operations Manager, AstraZeneca

  • Global human biological sample handling governance team
  • Sample collection strategies – clinical trial and commercial supply
  • “Decision tree” for sample retention
  • What industry wants?
  • 11:30 Biobanking for systems biology and stratified medicine

    Geraldine Thomas

    Geraldine Thomas, Professor of Molecular Pathology, Chernobyl Tissue Bank

  • Tissue samples on their own are no longer enough for researchers
  • Systems Biology Research and Stratified Medicine need annotation beyond the clinic and path lab
  • Biobanking strategies for "added value" - roles and responsibilities for biobankers and their customers
  • Data and metadata – why we need both
  • 12:10 Drug induced injury markers: What are the confounding effects by using pain relievers?

    Janine Swifka

    Janine Swifka, Staff Scientist Biobank, Bayer Pharma AG

  • Translational Biomarker
  • Drug induced injury markers
  • Frequently used analgesics and NSAIDS  and their possible influence on drug induced biomarker candidates
  • IMI – JU SAFE-T
  • 12:50 Networking Lunch

    14:00 Bridging the Biomarker Gap: Flexibility, Performance, Validation on the MSD Multi-Array Immunoassay Platform

    Chris Walker

    Chris Walker, Director International Scientific Support , Meso-Scale

  • Introduction to MSD technology – principles/instrumentation/reagents/performance advantages
  • MSD strategy to developing and validating immunoassays
  • Applications/products for use in pre-clinical and clinical studies and relevance to biobanking
  • MSD as a partner/collaborator
  • Final Conclusions
     
  • 14:40 From bench to clinic: the importance of healthy and diseased human tissue in discovering new therapeutics for respiratory disease

    Paul Whittaker

    Paul Whittaker, Unit Head for Pre-Clinical Biomarkers, Novartis Horsham Research Centre

  • Human tissue is a crucial element in the discovery and validation of new targets and biomarkers
  • Human tissue is a key link between animal model experiments and clinical studies
  • Human tissue from well-phenotyped patients is necessary for efficient biomarker qualification
  • 15:20 Afternoon Tea

    15:40 The business of biobanking

    Pedro  Rondot Radio

    Pedro Rondot Radio, Executive Director, University of Buenos Aires

    16:20 Building and developing a successful biobanking infrastructure – The Nottingham Health Science Biobank Experience

    Brian Thomson

    Brian Thomson, Director of Research and Development, University of Nottingham

  • Governance  - The Nottingham Health Science Biobank Experience
  • Public and Patient Involvement
  • Bioinformatic - The Nottingham Health Science Biobank Experience
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Julie Corfield

    Julie Corfield, Director, Areteva

    9:10 Dial "R" for Return: Individual Research Results and Incidental Findings in Population Biobanks

    Man H Zawati

    Man H Zawati , Lawyer and Academic Associate , McGill University Department of Human Genetics

  • Terminology: IRRs and IFs
  • Conditions of Return
  • Obligation or Professional Discretion?
  • Oversight Mechanisms
  • 9:50 Public-private partnerships enabling stratified medicine

    Julie Corfield

    Julie Corfield, Director, Areteva

  • Importance of Public-Private Partnerships with examples
  • Contribution by Biobanking and the STRATUM Project
  • Where will be 10 years from now?
  • 10:30 Morning Coffee

    10:50 Biobanks and compliance with data protection laws

    Daniel Cooper

    Daniel Cooper, Partner, Covington & Burling Llp

  • What is personal data?
  • Implications of data protection law for biobanks
  • Impact of the on-going revision of EU data protection law
  • 11:30 Use of Human Tissue - An Industry Perspective

    Derek McFerran

    Derek McFerran, Business Development Director, Tissue Solutions

  • The changing requirements for human samples
  • Trends in Types of Tissue/Biofluid
  • Shift towards fresh tissue
  • Ongoing Demand for Banked Samples
  • Growing Role of Biomarkers & Companion Diagnostics
  • 12:10 Regulation of biobanks in the UK

    Shaun Griffin

    Shaun Griffin, Director of Communications, Human Tissue Authority

    •  Introduction to the legal and regulatory requirements for biobanking for research and patient treatment

    •  How the HTA, MHRA, HRA / NRES, and others, work together to support biobanking in the UK

     

    12:45 Networking Lunch

    13:50 UCL biobanks and BioResource

    Kirstin Goldring

    Kirstin Goldring, Biobank Facilitator, University College London

  • Biobanking Facilities at UCL
  • UCL BioResource
  • Access to biobanks at UCL
  • 14:30 Tissue Access for Patient Benefit (TAPb): helping researchers access tissue donated by patients across UCL

    Amir Gander

    Amir Gander, Senoir Knowledge Transfer Associate, UCL Medical School Royal Free Campus

  • How UCL has improved the availability of human tissue to commercial researchers
  • Historical issues with tissue provision and future solutions
  • Beyond tissue provision, research, processing and analytical services
  • 15:10 Targets, Tissues and Information: biobanks and histology-based target identification in drug discovery

    Martyn Foster

    Martyn Foster, Independent Consultant in Experimental Pathology, Independent Consultancy

  • Framing the question and tissue selection criteria
  • Creating the target identification tissue set
  • What information is needed and why
  • The use of target identification data to enrich the biobank
  • 15:50 Chairman’s Closing Remarks and Afternoon Refreshments

    +

    FEATURED SPEAKERS

    Janine Swifka

    Janine Swifka

    Staff Scientist Biobank, Bayer Pharma AG
    Julie Corfield

    Julie Corfield

    Director, Areteva
    Paul Whittaker

    Paul Whittaker

    Unit Head for Pre-Clinical Biomarkers, Novartis Horsham Research Centre
    Pedro  Rondot Radio

    Pedro Rondot Radio

    Executive Director, University of Buenos Aires
    Shaun Griffin

    Shaun Griffin

    Director of Communications, Human Tissue Authority

    Amir Gander

    Senoir Knowledge Transfer Associate, UCL Medical School Royal Free Campus
    Amir Gander

    Balwir Matharoo Ball

    Operations Manager Trasitional Research & Biobanking, Nottingham University Hospitals NHS Trust
    Balwir Matharoo Ball

    Brian Thomson

    Director of Research and Development, University of Nottingham
    Brian Thomson

    Chris Walker

    Director International Scientific Support , Meso-Scale
    Chris Walker

    Daniel Cooper

    Partner, Covington & Burling Llp
    Daniel Cooper

    Derek McFerran

    Business Development Director, Tissue Solutions
    Derek McFerran

    Douglas McKechnie

    Biobank Operations Manager, AstraZeneca
    Douglas McKechnie

    Geraldine Thomas

    Professor of Molecular Pathology, Chernobyl Tissue Bank
    Geraldine Thomas

    Janine Swifka

    Staff Scientist Biobank, Bayer Pharma AG
    Janine Swifka

    Julie Corfield

    Director, Areteva
    Julie Corfield

    Kirstin Goldring

    Biobank Facilitator, University College London
    Kirstin Goldring

    Man H Zawati

    Lawyer and Academic Associate , McGill University Department of Human Genetics
    Man H Zawati

    Martyn Foster

    Independent Consultant in Experimental Pathology, Independent Consultancy
    Martyn Foster

    Nalin Thakker

    Associate Vice-President Compliance, Risk & Research Integrity, University of Manchester
    Nalin Thakker

    Paul Whittaker

    Unit Head for Pre-Clinical Biomarkers, Novartis Horsham Research Centre
    Paul Whittaker

    Pedro Rondot Radio

    Executive Director, University of Buenos Aires
    Pedro  Rondot Radio

    Peter Jackson

    Managing Director, Elpro UK Ltd
    Peter Jackson

    Shaun Griffin

    Director of Communications, Human Tissue Authority
    Shaun Griffin

    Workshops

    Regulation, Governance and Ethical Review of Biobanks
    Workshop

    Regulation, Governance and Ethical Review of Biobanks

    Copthorne Tara Hotel
    26th June 2013
    London, United Kingdom

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.